Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by Hormozgan University of Medical Sciences.
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Hormozgan University of Medical Sciences
Information provided by:
Hormozgan University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT00432588
First received: February 6, 2007
Last updated: May 31, 2007
Last verified: February 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hypothesis (H0): Labor duration and obstetric complications are not significantly different in the three groups (misoprostol-dinoprostone-oxytocin).
| Condition | Intervention | Phase |
|---|---|---|
|
Preeclampsia Fetal Death Fetal Membranes, Premature Rupture |
Drug: misoprostol Drug: dinoprostone |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Hormozgan University of Medical Sciences:
Eligibility| Genders Eligible for Study: | Female |
Criteria
Inclusion Criteria:
- Term pregnancy
- Singleton
- Vertex
- Bishop score below 6
Exclusion Criteria:
- History of drug reaction
- Medical disease
- IUGR
- Oligohydramnios
- Vaginal bleeding
- Fetal anomaly
- Uterine scar
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00432588
Locations
| Iran, Islamic Republic of | |
| Shariaty Maternity Hospital | Not yet recruiting |
| Tehran, Iran, Islamic Republic of | |
| Contact: Mitra Ahmad Soltani, MD 0098 021 22301004 m_a_sol@yahoo.com | |
Sponsors and Collaborators
Hormozgan University of Medical Sciences
Investigators
| Principal Investigator: | Mitra Ahmad Soltani | Hormozgan University of Medical Sciences |
| Study Chair: | Minoo Rajaee Lari, Perinatologist - Obs and Gyn | Department of Obs and Gyn - HUMS |
More Information
Additional Information:
Related Info 
No publications provided
| ClinicalTrials.gov Identifier: | NCT00432588 History of Changes |
| Other Study ID Numbers: | Misoprostol vs Dinoprostone |
| Study First Received: | February 6, 2007 |
| Last Updated: | May 31, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Hormozgan University of Medical Sciences:
|
IUFD POSTTERM ROM |
Additional relevant MeSH terms:
|
Fetal Death Fetal Membranes, Premature Rupture Pre-Eclampsia Rupture Pregnancy Complications Death Pathologic Processes Obstetric Labor Complications Hypertension, Pregnancy-Induced Wounds and Injuries Dinoprostone |
Misoprostol Oxytocics Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses Anti-Ulcer Agents Gastrointestinal Agents Abortifacient Agents, Nonsteroidal Abortifacient Agents |
ClinicalTrials.gov processed this record on May 16, 2013